Hemostasis and Tissue Sealing Agents Market, By Product Type (Topical Hemostats & Adhesives and Tissue Sealing Agents), By Application (Cardiovascular Surgery, Orthopedic Surgery, General Surgery, Neurosurgery, and Others), By End User (Hospitals, Ambulatory Surgical Centers, and Home Care Settings), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Dec 2023

Code : CMI1567

Pages :180

Formats :

Excel and PDF

Industry : Medical Devices

Market News

Recent Developments

New product launches/approvals

In July 2023, Baxter International Inc., a company focused on advancing surgical innovation, announced the launch of PERCLOT Absorbable Hemostatic Powder in the U.S. PERCLOT is a passive, absorbable hemostatic powder that is ready to use and designed for patients with intact coagulation to address mild bleeding.
In January 2023, Medcura, Inc., a medical device company, announced that the U.S. Food and Drug Administration (FDA) had granted the coveted breakthrough device designation for its LifeGel Absorbable Surgical Hemostat. LifeGel is the first and only hemostatic agent to receive breakthrough device designation seeking a new and highly differentiated indication: in surgical procedures (except in ophthalmic and urological) as an adjunctive hemostatic device.
In April 2022, Ethicon, part of Johnson & Johnson MedTech, announced the launch of the ENSEAL X1 Straight Jaw Tissue Sealer, a new advanced bipolar energy device that cuts and transects, enables stronger sealing, and captures more tissue per bite than the LigaSure Blunt Tip, a tissue sealing device from Medtronic.

Acquisitions

In 2021, BD, a global medical technology company, announced it had acquired Tissuemed, Ltd., a privately held firm headquartered in Leeds, England, that is an industry leader in developing self-adhesive surgical sealant films.
In 2021, Baxter International Inc. announced its Baxter Healthcare Corporation subsidiary had completed the acquisition of certain assets related to the PerClot Polysaccharide Hemostatic System from CryoLife, Inc., cardiac and vascular surgery company.
In February 2023, Advanced Medical Solutions Group plc, a global specialist in tissue-healing technologies, announced it had acquired Connexicon Medical Limited, a tissue adhesive technology specialist. The acquisition further strengthens AMS’s position in the US$ 300 million global tissue adhesive market, expands its product portfolio, and significantly enhances its technical and research and development capabilities in cyanoacrylate technology.